Company intelligence / Profile preview

Dano Pharmaceuticals

Suwon-si, Gyeonggi-do, South Korea

Ownership: Private
Development stage: Other

Overview

Dano Pharmaceuticals is a South Korean biotechnology company specializing in the development of innovative treatments for ophthalmic diseases. The company focuses on addressing unmet medical needs in conditions such as dry eye syndrome, glaucoma, and retinal diseases through its proprietary drug discovery and formulation technologies. Its lead program, DN-101, is currently in clinical development for the treatment of dry eye syndrome. Dano Pharmaceuticals aims to improve patient quality of life by providing more effective and convenient therapeutic options for vision-threatening conditions.

Therapeutic areas: Ophthalmology
Modalities: Small moleculeBiologicPeptide
Industry: Biotech

Beyond the preview

Go deeper on Dano Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dano Pharmaceuticals.

Explore the full profile